Omega Fund Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Omega Fund Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,971,241	Closed	-$5.01M	–	13
2023 Q1	$5.01M	Hold	1,971,241	–	–	3.27%	8
2022 Q4	$3.69M	Hold	1,971,241	–	–	1.24%	9
2022 Q3	$5.07M	Hold	1,971,241	–	–	1.86%	11
2022 Q2	$3.8M	Hold	1,971,241	–	–	1.21%	15
2022 Q1	$5.86M	Hold	1,971,241	–	–	1.2%	14
2021 Q4	$8.85M	Sell	1,971,241 -635,568	-24%	-$3.02M	1.25%	15
2021 Q3	$12.7M	Buy	2,606,809 +6,399	+0.2%	+$35.3K	1.42%	14
2021 Q2	$17.7M	Hold	2,600,410	–	–	2.01%	9
2021 Q1	$18.4M	Hold	2,600,410	–	–	1.74%	11
2020 Q4	$16.3M	Hold	2,600,410	–	–	2.44%	11
2020 Q3	$14.1M	Sell	2,600,410 -2,329	-0.1%	-$11.5K	3.81%	7
2020 Q2	$13.6M	Buy	2,602,739 +2,329	+0.1%	+$10.3K	3.71%	6
2020 Q1	$8.19M	Hold	2,600,410	–	–	3.39%	7
2019 Q4	$10.5M	Hold	2,600,410	–	–	3.34%	7
2019 Q3	$11.2M	Hold	2,600,410	–	–	3.47%	6
2019 Q2	$10.4M	Hold	2,600,410	–	–	2.65%	7
2019 Q1	$13.9M	Hold	2,600,410	–	–	4.47%	4
2018 Q4	$13.3M	Hold	2,600,410	–	–	9.89%	4
2018 Q3	$25.2M	Hold	2,600,410	–	–	11.93%	2
2018 Q2	$26.5M	Hold	2,600,410	–	–	19.57%	2
2018 Q1	$33.8M	Hold	2,600,410	–	–	33.22%	1
2017 Q4	$46.5M	Hold	2,600,410	–	–	33.65%	1
2017 Q3	$65.3M	Hold	2,600,410	–	–	36.93%	1
2017 Q2	$62.7M	Hold	2,600,410	–	–	39.11%	1
2017 Q1	$50.1M	Hold	2,600,410	–	–	32.54%	1
2016 Q4	$40M	Hold	2,600,410	–	–	32.5%	1
2016 Q3	$33.8M	Hold	2,600,410	–	–	25.83%	2
2016 Q2	$36.2M	Buy	2,600,410 +461,538	+22%	+$6.79M	26.83%	2
2016 Q1	$32.4M	Hold	2,138,872	–	–	22.51%	2
2015 Q4	$40.6M	Hold	2,138,872	–	–	22.58%	2
2015 Q3	$40.6M	Hold	2,138,872	–	–	22.88%	2
2015 Q2	$55.1M	Hold	2,138,872	–	–	27.83%	2
2015 Q1	$66.9M	Hold	2,138,872	–	–	28.91%	2
2014 Q4	$82.5M	Buy	+2,138,872	New	+$51.1M	37.93%	1

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Omega Fund Management's PRTK Position: Q2 2023 in Review

Omega Fund Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 1,971,241 shares — an estimated $5.01M sold.

Omega Fund Management first reported a position in PRTK in Q4 2014 and held it in 34 quarters. The position peaked at $82.5M in Q4 2014. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Omega Fund Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Omega Fund Management sold 1,971,241 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $5.01M.
Omega Fund Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 34 quarters.
Omega Fund Management's Paratek Pharmaceuticals, Inc. position peaked at $82.5M in Q4 2014.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Omega Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.